Taiho options rights to Arcus's immuno-oncology candidates; Options exercised
Arcus Biosciences Inc. granted Taiho Pharmaceutical Co. Ltd. an option to license exclusive rights in Asia (including Japan but excluding China) to develop and commercialize cancer immunotherapies from its pipeline.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com